| Medical and Health Sciences | Lifetime | 472 | CA 24 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 426 | CA 13 | 99.91 |
| Cardiology and Cardiovascular Medicine | Lifetime | 44 | CA 3 | 99.96 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 773 | CA 28 | 97.25 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 79 | CA 1 | 99.67 |
| Surgery | 2021-2025 | 311 | CA 19 | 97.88 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 466 | CA 18 | 85.99 |
| Orthopedics and Sports Medicine | 2021-2025 | 390 | CA 19 | 60.41 |
| Cardiovascular Function and Risk Factors | Lifetime | 36 | CA 2 | 99.92 |
| Heart Failure Treatment and Management | Lifetime | 17 | CA 2 | 99.93 |
| Cardiac pacing and defibrillation studies | Lifetime | 53 | CA 4 | 99.76 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 105 | CA 17 | 99.65 |
| Potassium and Related Disorders | Lifetime | 16 | CA 1 | 99.53 |
| Acute Myocardial Infarction Research | Lifetime | 164 | CA 10 | 99.46 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 251 | CA 16 | 99.28 |
| Blood Pressure and Hypertension Studies | Lifetime | 240 | CA 12 | 99.20 |
| Cardiac Arrhythmias and Treatments | Lifetime | 341 | CA 23 | 99.04 |
| Cardiac Imaging and Diagnostics | Lifetime | 512 | CA 21 | 99.17 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 528 | CA 55 | 98.69 |
| Diabetes Treatment and Management | Lifetime | 316 | CA 12 | 98.77 |
| Lipoproteins and Cardiovascular Health | Lifetime | 344 | CA 25 | 98.51 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 345 | CA 21 | 98.35 |
| Hormonal Regulation and Hypertension | Lifetime | 738 | CA 26 | 97.08 |
| Electrolyte and hormonal disorders | Lifetime | 452 | CA 19 | 96.21 |
| Heart rate and cardiovascular health | Lifetime | 54 | CA 4 | 96.03 |
| Medication Adherence and Compliance | Lifetime | 488 | CA 27 | 93.89 |
| Biomarkers in Disease Mechanisms | Lifetime | 695 | CA 19 | 83.16 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 111 | CA 3 | 99.20 |
| Heart Failure Treatment and Management | 2021-2025 | 62 | CA 3 | 99.41 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 124 | CA 17 | 98.30 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 99 | CA 6 | 98.68 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 97 | CA 5 | 97.60 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 202 | CA 10 | 95.59 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 358 | CA 12 | 94.64 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 699 | CA 42 | 95.28 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 1,000 | CA 16 | 93.99 |
| Diabetes Treatment and Management | 2021-2025 | 694 | CA 36 | 93.04 |
| Potassium and Related Disorders | 2021-2025 | 196 | CA 10 | 83.62 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 596 | CA 46 | 80.20 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 696 | CA 28 | 79.47 |
